Cardiol Therapeutics Inc Class A has seen its stock price drop significantly, closing down 2.87% today.
In the latest trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) closed at CA$1.69, reflecting a loss of 2.87%. This decline raises concerns about the company's market position and how investors feel about it.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Cardiol Therapeutics faces challenges, indicating potential issues that could impact future performance.
CRDL.TO Closes at CA$1.69 After 2.87% Drop
With a market cap of CA$194.81 million, Cardiol's stock performance today highlights broader worries about its growth potential and how the market perceives it.
Bull case
Despite today’s losses, Cardiol Therapeutics is making progress in clinical research, particularly with its Phase II study on recurrent pericarditis. If future trials go well, this could lead to positive developments for the company.
Bear case
The recent drop in stock price might reflect declining investor confidence, especially given the absence of positive news or catalysts to boost the stock.
Market Reaction to Cardiol's Performance
The 2.87% decline in Cardiol Therapeutics' stock today suggests a broader market sentiment questioning the company’s growth prospects. Investors often respond to stock performance based on the latest news and developments, and with no significant updates from the company, this drop raises concerns.
Current Developments and Future Outlook
While Cardiol has made strides in its clinical trials, such as the Phase II study on recurrent pericarditis, the lack of recent positive news may be contributing to the stock's decline. Investors should watch for upcoming announcements and trial results that could affect the company’s stock performance in the future.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
